Literature DB >> 28203411

Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis.

Shan-Shan Chen1, Zhao-Fang Yin1, Tao Chen2, Hui Qiu2, Ya-Ru Wei2, Shan-Shan Du2, Yue-Ping Jin2, Meng-Meng Zhao2, Qin Wu2, Dong Weng2, Hui-Ping Li2.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with severe pulmonary fibrosis. The main cause of IPF-associated death is acute exacerbation of IPF (AE-IPF). This study aims to develop a rat model of AE-IPF by two intratracheal perfusions with bleomycin (BLM).
METHODS: Ninety male Sprague Dawley (SD) rats were randomized into three groups: an AE-IPF model group (BLM + BLM group), an IPF model group (BLM group), and a normal control group. Rats in the BLM + BLM group underwent a second perfusion with BLM on day 28 after the first perfusion with BLM. Rats in the other two groups received saline as the second perfusion. Six rats in each group were sacrificed on day 31, day 35, and day 42 after the first perfusion, respectively. Additional 18 rats in each group were observed for survival.
RESULTS: Rats in the BLM + BLM group had significantly worse pulmonary alveolar inflammation and fibrosis than rats in the BLM group. Rats in the BLM + BLM group also developed large amounts of hyaline membrane, showed high levels of albumin (ALB) and various inflammatory factors in the bronchoalveolar lavage fluid (BALF), and had markedly increased lung water content. Furthermore, rat survival was reduced in the BLM + BLM group. The pathophysiological characteristics of rats in the BLM + BLM group resemble those of patients with AE-IPF.
CONCLUSIONS: A second perfusion with BLM appears to induce acute exacerbation of pulmonary fibrosis and may be used to model AE-IPF in rats.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis (IPF); acute exacerbation; bleomycin (BLM); model

Year:  2017        PMID: 28203411      PMCID: PMC5303074          DOI: 10.21037/jtd.2017.01.22

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  30 in total

Review 1.  IPF: new insight on pathogenesis and treatment.

Authors:  S Harari; A Caminati
Journal:  Allergy       Date:  2010-02-01       Impact factor: 13.146

2.  ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits.

Authors:  Katsuya Mikawa; Kahoru Nishina; Yumiko Takao; Hidefumi Obara
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

3.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

4.  Design and Synthesis of N-Arylphthalimides as Inhibitors of Glucocorticoid-Induced TNF Receptor-Related Protein, Proinflammatory Mediators, and Cytokines in Carrageenan-Induced Lung Inflammation.

Authors:  Mashooq A Bhat; Mohamed A Al-Omar; Mushtaq A Ansari; Khairy M A Zoheir; Faisal Imam; Sabry M Attia; Saleh A Bakheet; Ahmed Nadeem; Hesham M Korashy; Andrey Voronkov; Vladimir Berishvili; Sheikh F Ahmad
Journal:  J Med Chem       Date:  2015-11-05       Impact factor: 7.446

5.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

6.  Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus.

Authors:  Tracy R McMillan; Bethany B Moore; Jason B Weinberg; Kevin M Vannella; W Brad Fields; Paul J Christensen; Linda F van Dyk; Galen B Toews
Journal:  Am J Respir Crit Care Med       Date:  2008-01-10       Impact factor: 21.405

7.  Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis.

Authors:  J S Wild; D M Hyde; S N Giri
Journal:  Pharmacol Toxicol       Date:  1994-07

8.  Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats.

Authors:  Lili Gao; Haiying Tang; Huanyu He; Jia Liu; Jingwei Mao; Hong Ji; Hongli Lin; Taihua Wu
Journal:  Front Pharmacol       Date:  2015-10-01       Impact factor: 5.810

9.  Mycobacteria bypass mucosal NF-kB signalling to induce an epithelial anti-inflammatory IL-22 and IL-10 response.

Authors:  Nataliya Lutay; Gisela Håkansson; Nader Alaridah; Oskar Hallgren; Gunilla Westergren-Thorsson; Gabriela Godaly
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway via miR-140 upregulation.

Authors:  Congjie Wang; Xiaodong Song; Youjie Li; Fang Han; Shuyan Gao; Xiaozhi Wang; Shuyang Xie; Changjun Lv
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more
  2 in total

1.  Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody.

Authors:  Dong Weng; Zhao-Fang Yin; Shan-Shan Chen; Xian He; Nan Li; Tao Chen; Hui Qiu; Meng-Meng Zhao; Qin Wu; Nian-Yu Zhou; Li-Qin Lu; Dan-Li Tang; Jia-Cui Song; Hui-Ping Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

2.  IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis.

Authors:  Tao Chen; Hui Qiu; Meng-Meng Zhao; Shan-Shan Chen; Qin Wu; Nian-Yu Zhou; Li-Qin Lu; Jia-Cui Song; Dan-Li Tang; Dong Weng; Hui-Ping Li
Journal:  J Cell Mol Med       Date:  2018-10-30       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.